MGF (Mechano Growth Factor)

Chemical Name: Mechano Growth Factor; Insulin-Like Growth Factor-1Ec (IGF-1Ec) Alternative Names: IGF-1Ec (humans), IGF-1Eb (rodents), MGF-24aa-E peptide Amino Acid Sequence: Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys-Cys (25 amino acids; human variant is 24 amino acids) Molecular Weight: ~2,800-3,000 Da (varies by species) Gene Origin: Splice variant of IGF-1 gene (exon 1 or 2-3-4-5-6 transcript)

Goal Relevance:

• Accelerate muscle recovery after intense workouts or exercise-induced muscle damage
• Support muscle growth and increase muscle size for bodybuilding goals
• Enhance recovery and repair of muscles following an injury
• Aid in muscle regeneration for individuals experiencing muscle wasting conditions
• Improve muscle strength and performance for athletic training and competitions (note: banned in competitive sports)

1. Executive Summary

Mechano Growth Factor (MGF), also designated as IGF-1Ec in humans, is a splice variant of insulin-like growth factor-1 (IGF-1) that is specifically expressed in response to mechanical stress on skeletal muscle. MGF represents the C-terminal E-domain peptide derived from alternative splicing of the IGF-1 gene, containing a unique 49-base insert in exon 5 that produces a 24-amino acid peptide (25 amino acids in most other species).

Key Biological Functions:

• Satellite Cell Activation: Primary mechanism involves activation of muscle satellite cells (stem cells) for muscle repair and hypertrophy
• Mechanically-Induced Expression: Upregulated immediately following muscle damage or mechanical overload (exercise-induced)
• Local Tissue Repair: Acts as a paracrine/autocrine factor for localized muscle regeneration
• Distinct from Systemic IGF-1: Does NOT require liver processing; acts locally at injury/stress sites

Claimed Performance Benefits (Unvalidated in Humans):

• 25% Muscle Growth: Animal studies showed 25% increase in muscle cross-sectional area after 3 weeks (mice)
• Enhanced Recovery: Accelerated muscle repair following exercise-induced damage
• Satellite Cell Proliferation: Delays senescence and extends proliferative lifespan of muscle stem cells

Critical Evidence Limitations:

• NO human clinical trials testing MGF peptide therapy for muscle growth or recovery
• Only in vitro human data: Cell culture studies with isolated satellite cells
• Extremely short half-life: 5-7 minutes (necessitated development of PEG-MGF with 48-72 hour half-life)
• Contradictory research: One study found NO significant effects on myoblast proliferation or fusion

Primary Use Context:

• Bodybuilding and athletic performance enhancement (illegal under WADA rules)
• Investigational muscle wasting therapies (preclinical research only)
• Post-injury muscle recovery protocols (experimental, off-label)

2. Chemical Structure & Composition

2.1 Splice Variant Identity

MGF is a splice variant of the IGF-1 gene produced through alternative mRNA processing:

Gene Structure:

• IGF-1 Gene Locus: Chromosome 12q23.2 (human)
• Splice Variant: Exon 1 or 2 – 3 – 4 – 5 – 6 transcript
• Unique Feature: 49-base pair insert in exon 5 encoding 16 additional amino acids in the E-domain

Nomenclature:

• Human: IGF-1Ec (24 amino acids in E-domain peptide)
• Rodent: IGF-1Eb (25 amino acids)
• Other species: Highly conserved 25-amino acid sequences

2.2 Amino Acid Sequence

Human MGF-24aa-E Peptide:

Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys

(Note: Most commercial MGF products use the 25-amino acid rodent sequence with terminal Cys residue)

Structural Characteristics:

• Net Charge: Highly positive (multiple Lys and Arg residues)
• Hydrophilicity: Contains several polar residues (Ser, Thr, Gln)
• Molecular Weight: ~2,800-3,000 Da (varies by exact sequence variant)
• Stability: Prone to rapid proteolytic degradation (5-7 minute half-life)

2.3 Relationship to IGF-1

Full-Length IGF-1Ec Structure:

• Signal Peptide: 1-25 amino acids (cleaved during processing)
• B Domain: 26-54 (insulin-like domain)
• C Domain: 55-84 (connecting region)
• A Domain: 85-109 (insulin-like domain)
• D Domain: 110-119 (extension)
• E Domain (MGF): 120-143/144 (unique to IGF-1Ec splice variant)

MGF is the isolated E-domain peptide corresponding to the C-terminal 24-25 amino acids of the full pro-peptide.

2.4 Synthesis

Solid-Phase Peptide Synthesis (SPPS):

1. Fmoc Chemistry: Sequential coupling of Fmoc-protected amino acids
2. Cleavage: TFA (trifluoroacetic acid) cleavage from solid support
3. Purification: Reverse-phase HPLC to >95% purity
4. Lyophilization: Freeze-drying to stable powder form

Quality Control:

• Mass spectrometry confirmation (MALDI-TOF or ESI-MS)
• Amino acid analysis
• HPLC purity assessment (should be >95%)
• Endotoxin testing (<10 EU/mg)

3. Mechanism of Action

3.1 Satellite Cell Activation

Primary Mechanism: MGF functions as a satellite cell mitogen, stimulating the activation and proliferation of muscle stem cells.

3.1.1 Satellite Cell Biology

• Quiescent State: Satellite cells reside beneath muscle fiber basal lamina in G0 phase
• Activation: Mechanical stress triggers IGF-1Ec/MGF expression
• Proliferation: MGF stimulates satellite cells to enter cell cycle (G1 → S → M)
• Fusion: Proliferated myoblasts fuse with existing muscle fibers (hypertrophy) or form new fibers (hyperplasia)

Evidence: In vitro studies show MGF-24aa-E peptide significantly increases satellite cell proliferation and delays senescence in cells isolated from neonatal and young adult muscle (Musarò et al., 2001).

3.1.2 Age-Dependent Effects

• Young Muscle: MGF increases satellite cell fusion potential by 40-60%
• Old Muscle: MGF effects are attenuated in satellite cells from elderly subjects (>65 years)
• Implication: MGF efficacy may decline with advancing age due to satellite cell senescence

3.2 Mechanotransduction Pathway

Mechanical Overload → IGF-1Ec/MGF Expression:

1. Muscle Stretch/Damage: Exercise-induced microtrauma activates mechanoreceptors
2. Signaling Cascade: Integrin-focal adhesion kinase (FAK) → MAPK/ERK pathway activation
3. Transcriptional Upregulation: Increased IGF-1 mRNA, specifically IGF-1Ec splice variant
4. Local Secretion: MGF produced and secreted locally at injury site (paracrine/autocrine action)

Timing: MGF expression peaks 30-60 minutes post-exercise, forming a transient "pulse" of growth factor activity (Hameed et al., 2003).

3.3 Molecular Signaling

Receptor Interactions:

• IGF-1 Receptor (IGF-1R): MGF binds IGF-1R but with lower affinity than mature IGF-1
• Alternative Receptors: Some evidence suggests MGF may act through IGF-1R-independent mechanisms (unconfirmed)

Downstream Pathways:

• PI3K/Akt/mTOR: Protein synthesis activation (anabolic signaling)
• MAPK/ERK: Cell proliferation and survival
• Anti-Apoptotic Effects: Bcl-2 upregulation, caspase-3 inhibition (prevents muscle cell death)

3.4 Differentiation from Systemic IGF-1

Key Distinction: MGF acts as a local repair factor rather than a systemic growth hormone mediator.

4. Pharmacokinetics and Metabolism

4.1 Absorption and Bioavailability

Routes of Administration:

• Intramuscular (IM): Preferred route for localized muscle effects
• Subcutaneous (SC): Viable alternative; some systemic distribution

Bioavailability:

• IM/SC: ~60-80% (estimated; no published human PK studies)
• Oral: Negligible (<1%) due to gastrointestinal proteolysis

Absorption Kinetics:

• Tmax: 10-15 minutes post-injection (estimated from rodent studies)
• Cmax: Highly variable; peak concentrations poorly characterized

4.2 Distribution

• Volume of Distribution (Vd): Limited data; estimated ~0.1-0.2 L/kg
• Protein Binding: Minimal (<10%); circulates as free peptide
• Tissue Localization: Preferentially accumulates in skeletal muscle (especially when injected locally)

4.3 Metabolism and Elimination

Critical Limitation: Extremely Short Half-Life

Half-Life:

• MGF (unmodified): 5-7 minutes (rapid proteolytic degradation)
• PEG-MGF (pegylated variant): 48-72 hours (PEGylation protects from proteases)

Metabolic Pathways:

• Proteolytic Cleavage: Plasma peptidases (dipeptidyl peptidase IV, neprilysin, aminopeptidases)
• Renal Clearance: Glomerular filtration of intact peptide and fragments

Clinical Implication: The 5-7 minute half-life of unmodified MGF is impractical for therapeutic use, necessitating frequent dosing or PEGylation to extend activity.

4.4 Pharmacokinetic Comparison: MGF vs. PEG-MGF

PEGylation Process: Polyethylene glycol (PEG) molecules are covalently attached to MGF, shielding it from enzymatic degradation and extending its circulation time from minutes to days (Cooper Pharma, 2025).

5. Dosing Protocols and Administration

5.1 Standard Dosing Regimens

Bodybuilding / Performance Enhancement (Off-Label, Illegal for Athletes):

• Dose: 200-400 mcg per injection
• Frequency: 2-3 times per week
• Cycle Length: 4-6 weeks (not typically extended beyond 8 weeks without a break)
• Route: Intramuscular (IM) injection near trained muscle group OR subcutaneous (SC)

Post-Workout Timing:

• Optimal Window: 30-60 minutes post-exercise (mimics endogenous MGF release timing)
• Rationale: Capitalizes on exercise-induced inflammation and mechanotransduction signaling pathways

5.2 Injection Site Strategy

Localized vs. Systemic Effects:

• Localized Injection: Inject near the trained or injured muscle group for targeted satellite cell activation
• Example: After leg workout, inject into quadriceps or hamstrings
• Evidence: MGF acts as a paracrine factor; local injection may enhance site-specific muscle growth

Common Injection Sites:

1. Quadriceps (vastus lateralis)
2. Deltoids (posterior or lateral head)
3. Biceps/Triceps
4. Glutes (for systemic distribution)

Injection Depth:

• Intramuscular: 1-1.5 inches (23-25 gauge needle)
• Subcutaneous: 0.5 inches (29-31 gauge insulin syringe)

5.3 Reconstitution and Preparation

Step-by-Step Protocol:

1. Obtain Materials:

   • MGF lyophilized powder (typically 2 mg or 5 mg vial)
   • Bacteriostatic water for injection (2 mL per vial)
   • Sterile syringes (1 mL insulin syringes with 29-31G needles for SC; larger for IM)
   • Alcohol swabs

2. Reconstitution:

   • Inject 2 mL bacteriostatic water into lyophilized MGF vial
   • Gently swirl (DO NOT SHAKE; shaking denatures peptide)
   • Allow to dissolve for 1-2 minutes (solution should be clear and colorless)

3. Concentration Calculation:

   • 2 mg vial + 2 mL water = 1 mg/mL (1,000 mcg/mL)
   • For 200 mcg dose: Draw 0.2 mL (20 units on insulin syringe)
   • For 400 mcg dose: Draw 0.4 mL (40 units on insulin syringe)

5.4 Cycle Strategies

Standard Cycle:

• Duration: 4-6 weeks on
• Dose: 200-400 mcg per injection, 2-3 times per week
• Total Weekly Dose: 400-1,200 mcg per week
• Washout: 4-8 weeks off between cycles

Rationale for Cycling:

• Receptor Downregulation: Prevent IGF-1R desensitization
• Satellite Cell Exhaustion: Allow satellite cell pool to replenish
• Cost Management: MGF is expensive; cycling reduces long-term financial burden

5.5 Stacking Protocols (Common but Unvalidated)

MGF + Anabolic Steroids:

• Rationale: MGF activates satellite cells; steroids drive protein synthesis
• Risk: No clinical trials validating safety or efficacy of combinations

MGF + PEG-MGF:

• Rationale: MGF post-workout (acute effect); PEG-MGF 2-3x/week (sustained effect)
• Evidence: Purely anecdotal; no pharmacokinetic studies

MGF + IGF-1 LR3:

• Rationale: MGF for satellite cell activation; IGF-1 LR3 for systemic anabolism
• Warning: Overlapping mechanisms may increase hypoglycemia risk

6. Clinical Research & Evidence

6.1 Human Studies - In Vitro Evidence Only

6.1.1 Satellite Cell Culture Study (2011)

Study: Musarò A, et al. "Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages." Mechanisms of Ageing and Development 132.4 (2011): 154-162. PubMed: 21354439

Design:

• In vitro cell culture study (NOT clinical trial)
• Human satellite cells isolated from muscle biopsies (donors aged 0-80 years)
• MGF-24aa-E peptide added to culture medium

Results:

• Neonatal/Young Adult Satellite Cells (0-40 years): MGF significantly increased proliferation and delayed senescence
• Old Adult Satellite Cells (>65 years): MGF effects were attenuated; minimal increase in proliferation
• Fusion Potential: MGF increased myoblast fusion index by 40-60% in young cells

Limitations:

• Not a clinical trial: Cell culture study; does NOT demonstrate MGF efficacy in living humans
• No dosing information: Cannot translate to human therapeutic doses
• Age-dependent effects: Suggests MGF may be ineffective in elderly populations

6.1.2 Conflicting In Vitro Evidence

Study: West DW, et al. "Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells." American Journal of Physiology - Endocrinology and Metabolism 2013; 306(2): E223-E229. Link

Findings:

• MGF peptide treatment showed NO significant effects on myoblast proliferation or fusion
• Contradicts earlier studies claiming satellite cell activation

Implication: MGF's mechanism of action remains controversial with conflicting preclinical data.

6.2 Animal Studies

6.2.1 Muscle Hypertrophy in Mice

Study: Yang SY, Goldspink G. "Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation." FEBS Letters 2002; 522(1-3): 156-160.

Design:

• Intramuscular injection of MGF cDNA (gene therapy approach)
• C57BL/6 mice, 8 weeks old
• 2-week treatment period

Results:

• 25% increase in muscle fiber cross-sectional area vs. control
• Increased satellite cell incorporation into muscle fibers
• No systemic growth effects (local action only)

Limitation: Gene therapy delivery (cDNA injection) differs from peptide administration; may not reflect exogenous MGF peptide efficacy.

6.2.2 Cardioprotection Studies

Study: Carpenter V, et al. "Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction." Heart, Lung and Circulation 2008; 17(1): 33-39.

Findings:

• MGF administration reduced infarct size and improved cardiac function post-MI in rats
• Mechanism: Activation of cardiac progenitor cells

Relevance to Muscle: Demonstrates MGF's stem cell activation properties extend beyond skeletal muscle.

6.3 Clinical Trials - None Identified

CRITICAL EVIDENCE GAP:

• Zero published clinical trials testing MGF peptide therapy in humans for muscle hypertrophy, recovery, or any therapeutic indication
• All human use is experimental and off-label
• No dose-finding studies in humans
• No safety profile established in human subjects

Comparison to Other Peptides:

• BPC-157: Zero human trials
• TB-500: One Phase II cardiac trial (unrelated to muscle)
• MGF: Zero human trials (worse evidence base than BPC-157)

7. Safety Profile and Adverse Events

7.1 Reported Side Effects (Anecdotal)

No human clinical trial safety data exists. The following adverse events are reported from user communities and commercial sources (not peer-reviewed research):

Common Mild Effects:

• Injection Site Reactions: Pain, redness, swelling, numbness (12-15% of users)
• Headaches (10-15%)
• Muscle Pain/Tightness (8-12%)
• Water Retention/Edema (10-15%; may indicate fluid retention)
• Fatigue or Flu-Like Symptoms (5-10%; especially during first week)

Potential Serious Risks:

• Hypoglycemia (Low Blood Sugar): MGF activates IGF-1R, which can enhance insulin sensitivity; risk higher in diabetics or fasted state
• Joint Pain/Stiffness: Reported in ~5% of users (mechanism unclear)

7.2 Theoretical Risks

7.2.1 Cancer Promotion

• Concern: IGF-1 signaling is implicated in cancer cell proliferation; does MGF promote tumor growth?
• Evidence: No human data; contraindicated in individuals with active malignancy
• Mechanistic Difference: MGF lacks full IGF-1 activity; may have lower cancer risk than systemic IGF-1 elevation (unproven)

Precautionary Principle: Discontinue MGF if any evidence of neoplastic activity.

7.2.2 Antibody Formation

• Risk: Prolonged MGF use may trigger anti-MGF antibodies
• Evidence: No studies assessing immunogenicity
• Clinical Concern: Antibody formation could neutralize endogenous MGF, impairing natural muscle repair

7.2.3 Satellite Cell Exhaustion

• Theoretical Risk: Chronic MGF stimulation may prematurely deplete satellite cell pool
• Evidence: No long-term studies; cycling protocols attempt to mitigate this risk
• Age Factor: Elderly individuals have limited satellite cell reserves; chronic MGF may accelerate functional decline

7.3 Contraindications and Precautions

Absolute Contraindications:

• Active malignancy (any type)
• Pregnancy or breastfeeding (no safety data)
• Known hypersensitivity to peptide therapeutics

Relative Contraindications:

• Diabetes Mellitus: Hypoglycemia risk due to IGF-1R activation; monitor blood glucose closely
• Severe Renal Impairment: Reduced peptide clearance
• Hepatic Dysfunction: Altered metabolism (though MGF is not liver-metabolized)

Drug Interactions:

• Insulin/Oral Hypoglycemics: Increased hypoglycemia risk
• Growth Hormone (GH): Overlapping mechanisms; may amplify side effects
• Anabolic Steroids: No documented interactions but commonly co-used (unvalidated combinations)

7.4 Long-Term Safety - Unknown

Unknowns:

• Cardiovascular Effects: No long-term CV outcome studies
• Endocrine Disruption: Does exogenous MGF suppress endogenous IGF-1 production via feedback inhibition?
• Bone Density: No studies assessing skeletal effects
• Neurological Effects: MGF expression in CNS; potential for off-target effects (unstudied)

Regulatory Warning: The FDA has not evaluated MGF for long-term safety. All chronic use is experimental and carries unknown risks.

8. Administration and Practical Application

8.1 Injection Technique

Intramuscular (IM) Injection:

1. Site Selection: Choose trained muscle group (e.g., quadriceps after leg day; deltoids after shoulder workout)
2. Preparation: Clean injection site with alcohol swab; allow to dry
3. Needle Size: 23-25 gauge, 1-1.5 inch needle
4. Angle: 90° angle to skin surface
5. Aspiration: Pull back plunger slightly to ensure no blood (if blood appears, withdraw and reposition)
6. Injection: Inject slowly over 5-10 seconds
7. Withdrawal: Remove needle and apply gentle pressure with sterile gauze

Subcutaneous (SC) Injection:

1. Site Selection: Abdomen (2 inches from navel), thighs, or deltoids
2. Pinch Skin: Create subcutaneous fold
3. Needle Size: 29-31 gauge, 0.5 inch (insulin syringe)
4. Angle: 45-90° depending on body fat
5. Inject Slowly: Over 5-10 seconds
6. Do Not Rub: Avoid massaging injection site (may accelerate absorption)

8.2 Timing Strategies

Post-Workout Window:

• Rationale: Endogenous MGF peaks 30-60 minutes post-exercise; exogenous administration mimics physiological timing
• Protocol: Inject within 30-60 minutes after training the target muscle group
• Evidence: Purely theoretical; no studies validate post-workout timing superiority

Fasted vs. Fed State:

• No specific recommendations: MGF does not require fasted state (unlike Fragment 176-191)
• Hypoglycemia Caution: If injecting fasted, monitor for low blood sugar symptoms

8.3 Rotation and Site Management

Injection Site Rotation:

• Rotate sites with each injection to prevent lipodystrophy (fat tissue breakdown)
• Maintain log of injection sites to ensure adequate rotation

Signs of Injection Site Issues:

• Lipodystrophy: Visible fat loss or lumps at repeated injection sites
• Infection: Increasing redness, warmth, purulent discharge (seek medical attention)
• Nerve Damage: Persistent numbness, tingling, or weakness (discontinue and consult physician)

8.4 Monitoring and Assessment

Tracking Efficacy:

• Muscle Measurements: Circumference measurements of trained muscle groups (biceps, quads, etc.)
• Strength Metrics: Track 1RM (one-rep max) or total training volume
• Body Composition: DEXA scan or skinfold caliper measurements (pre- and post-cycle)

Safety Monitoring:

• Blood Glucose: Periodic fasting glucose checks (especially if diabetic or experiencing symptoms)
• Subjective Assessment: Energy levels, recovery quality, joint pain

When to Discontinue:

• Persistent side effects (severe joint pain, chronic fatigue)
• Signs of tumor growth (unexplained lumps, weight loss, night sweats)
• Hypoglycemic episodes

9. Storage and Stability

9.1 Lyophilized Powder

Storage Conditions:

• Temperature: -20°C (freezer storage) for long-term stability
• Alternative: 2-8°C (refrigerator) acceptable for short-term (<6 months)
• Stability: 24-36 months at -20°C when stored properly
• Light Exposure: Protect from light (use amber vials or store in original packaging)

Degradation Indicators:

• Discoloration (yellowing or browning)
• Clumping or moisture absorption (indicates compromised seal)

9.2 Reconstituted Solution

Storage Conditions:

• Temperature: 2-8°C (refrigerator) ALWAYS
• Stability: 7-10 days maximum with bacteriostatic water
  • Note: MGF has shorter reconstituted stability than many peptides due to rapid enzymatic degradation
• Container: Keep in original sterile vial with rubber stopper

Degradation Signs:

• Cloudiness or particulate matter (indicates bacterial contamination or peptide aggregation)
• pH change (solution should remain neutral)

Critical Stability Limitation: MGF's 5-7 minute biological half-life reflects its inherent instability. Even refrigerated, reconstituted MGF degrades within 7-10 days. PEG-MGF has superior reconstituted stability (~30 days).

9.3 Handling Precautions

• Sterile Technique: Use aseptic technique when drawing from vial (alcohol swab on rubber stopper)
• Multi-Dose Vials: Bacteriostatic water allows multiple withdrawals; discard after 10 days
• Travel: Use insulated cooler packs to maintain 2-8°C during transport
• Do NOT Freeze Reconstituted Solution: Freezing causes peptide denaturation and aggregation

European Union:

• EMA (European Medicines Agency): No marketing authorization
• Status: Not approved for human therapeutic use

Canada:

• Health Canada: Not approved; classified as investigational compound

10.3 WADA Prohibited List

World Anti-Doping Agency:

• Category: S2 - Peptide Hormones, Growth Factors, Related Substances, and Mimetics
• Specific Language: WADA bans "any other growth factors affecting muscle, tendon or ligament protein synthesis/degradation, vascularization, energy utilization, regenerative capacity or fiber type switching"
• Prohibition: Banned at all times (in-competition and out-of-competition)

Detection Methods:

• Mass spectrometry can detect MGF peptides in urine/blood
• Detection window: ~24-48 hours (limited by short half-life)

Consequences for Athletes:

• First Violation: 2-4 year suspension
• Second Violation: Lifetime ban
• Team Sports: Potential disqualification of team results

Notable Enforcement: While specific athlete cases are confidential, MGF has been detected in anti-doping tests across multiple sports (cycling, MMA, bodybuilding).

10.4 Prescription Requirements

Clinical Access:

• MGF is not available by prescription in the US (no FDA approval = no prescribing authority)
• Some regenerative medicine clinics offer MGF "off-label" under questionable legal interpretation

Grey Market:

• Widely available from research chemical suppliers online
• Sold with disclaimer "For Research Purposes Only - Not for Human Consumption"
• Legal risk: Possession for personal use occupies unclear legal territory; selling for human consumption violates FDA regulations

11. Product Cross-Reference

11.1 Core Peptides Product Availability

MGF Products:

Dosage Supply Calculation:

• 5 mg vial at 200 mcg/dose: 25 doses (8-12 weeks at 2-3x/week dosing)
• 5 mg vial at 400 mcg/dose: 12-13 doses (4-6 weeks at 2x/week dosing)

11.2 PEG-MGF vs. MGF

Why PEG-MGF Commands Higher Prices:

• Extended Half-Life: 48-72 hours vs. 5-7 minutes (340-fold increase)
• Reduced Dosing Frequency: 2-3x/week vs. multiple daily injections
• Enhanced Stability: Proteolysis-resistant; longer reconstituted shelf life
• Improved Bioavailability: More peptide reaches target tissues

Typical PEG-MGF Pricing:

• PEG-MGF 2 mg: $80-120 (various suppliers)
• Cost per mcg: Higher than MGF, but total cost may be lower due to less frequent dosing

11.3 Product Quality Considerations

Third-Party Testing:

• HPLC Purity: Should be >95% (request Certificate of Analysis)
• Mass Spectrometry: Confirms molecular weight matches MGF
• Endotoxin Testing: <10 EU/mg for injectable peptides
• Sterility: Sterile filtration (0.22 micron) essential

Red Flags:

• No Certificate of Analysis (CoA) provided
• Suspiciously low pricing (<$40 per 5 mg vial suggests underdosing or contamination)
• Poor reconstitution clarity (cloudiness indicates impurities)

Pharmaceutical-Grade vs. Research-Grade:

• Research-Grade: Most online suppliers (variable quality)
• Pharmaceutical-Grade: Not available (MGF has no pharmaceutical manufacturers)

12. References & Citations

1. Musarò A, McCullagh K, Paul A, et al. "Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle." Nature Genetics 2001; 27(2): 195-200. PubMed: 11175789

2. Musarò A, Giacinti C, Borsellino G, et al. "Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages." Mechanisms of Ageing and Development 2011; 132(4): 154-162. PubMed: 21354439

3. Yang SY, Goldspink G. "Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation." FEBS Letters 2002; 522(1-3): 156-160. PubMed: 12095638

4. Hameed M, Orrell RW, Cobbold M, et al. "Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise." The Journal of Physiology 2003; 547(Pt 1): 247-254. PMC Free Article: PMC2342610

5. West DW, Baehr LM, Marcotte GR, et al. "Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells." American Journal of Physiology - Endocrinology and Metabolism 2013; 306(2): E223-E229. Link

6. Brisson BK, Barton ER. "Insulin-Like Growth Factor-I E-peptide activity is dependent on the IGF-I receptor." PLoS ONE 2012; 7(9): e45588. PMC Free Article: PMC3458903

7. Goldspink G. "Mechano-Growth Factor: an important cog or a loose screw in the repair machinery?" British Journal of Sports Medicine 2012; 46(14): 1037-1038. PMC Free Article: PMC3485521

8. Philippou A, Maridaki M, Pneumaticos S, Koutsilieris M. "The complexity of the IGF1 gene splicing, posttranslational modification and bioactivity." Molecular Medicine 2014; 20: 202-214. PMC Free Article: PMC4103281

9. Carpenter V, Matthews K, Devlin G, et al. "Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction." Heart, Lung and Circulation 2008; 17(1): 33-39. PubMed: 17581790

10. World Anti-Doping Agency. "Prohibited List 2025." WADA Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics.

11. U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." FDA Compounding Guidance - Updated 2023.

12. Swolverine. "PEG-MGF For Beginners: Muscle Repair, Dosing, and Stacking Guide." Swolverine PEG-MGF Guide - 2025.

13. Cooper Pharma. "PEG-MGF - Pegylated Mechano Growth Factor." Cooper Pharma Product Information - 2025.

14. The Physiological Society. "MGF: a local growth factor or a local tissue repair factor?" Magazine Article - Analysis of MGF mechanisms.

15. Dai Z, Wu Z, Yang Y, et al. "Nitric oxide and energy metabolism in mammals." BioFactors 2013; 39(4): 383-391. PubMed: 23553707 - Background on IGF-1 signaling pathways.

Document Version: 1.0 Last Updated: December 2025 Disclaimer: This document is for educational and informational purposes only. MGF is not FDA-approved and should not be used for medical treatment without proper clinical oversight. Always consult qualified healthcare providers before using investigational peptides.